A Phase 2 Study of Vapendavir in Asthmatic Adults With Symptomatic Human Rhinovirus Infection
Status:
Completed
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
This Phase 2 protocol is designed to compare two dose levels of Vapendavir versus placebo.
The objectives are to obtain safety and efficacy data in moderate to severe asthmatic
patients, aged 18 to 75 years at risk of loss of asthma control due to presumptive Human
Rhinovirus infection.